GLP-1 Drugs Suppress Your Antidiuretic Hormone: A New Link to Water Balance

Secondary analysis of two randomized, double-blind, placebo-controlled crossover trials. Fifty-four participants (34 with primary polydipsia, 20 healthy) received 3 weeks of dulaglutide 1.5 mg or placebo subcutaneously once weekly, with blood drawn at 08:00 after each treatment phase. Within-subject copeptin differences were analyzed using the Wilcoxon rank test.

GLP-1 drugs are known to affect fluid balance — patients often drink less and urinate less — but the mechanism was unknown. This study provides the first direct link between GLP-1 signaling and vasopressin suppression, explaining a physiological effect that affects millions of people taking these drugs. It also opens new therapeutic possibilities for conditions involving vasopressin dysregulation, like primary polydipsia.

As GLP-1 drugs are prescribed to tens of millions of people worldwide, understanding all their physiological effects becomes critical. This study adds vasopressin suppression to the growing list of GLP-1 actions beyond blood sugar and weight control. It could also inform treatment of conditions like primary polydipsia (excessive water drinking) and potentially hyponatremia.

This is a secondary analysis — the original trials were not designed to assess vasopressin effects. The sample size of 54 is modest, and the 3-week duration may not capture long-term effects. The p-value of 0.047 is borderline significant. Participants were young (median age 27), lean (median BMI 23), and predominantly female (63%), limiting generalizability to older or obese populations typical of GLP-1 drug users.